SION Stock Forecast & Price Target

Sionna Therapeutics is viewed positively because the 14-day study showed a stronger sweat chloride response after excluding outliers, improving from -1.0 to -3.8 mmol/L and even -8.6 mmol/L in a secondary analysis, suggesting the underlying biology may be more robust than the headline result implied. The apparent non-adherence in a small, short-duration trial and possible drug-drug interaction concerns with SION-719 and Trikafta appear less troubling when compared with the planned SION-451/SION-2222 regimen, which management believes should avoid that exposure issue. That combination, together with the company’s focus on CFTR normalization through complementary mechanisms, supports a credible path toward clinically meaningful benefits in cystic fibrosis.

Sionna Therapeutics is viewed negatively because its Phase 2a PreciSION study failed to meet the sweat chloride endpoint, with SION-719 showing a placebo-adjusted change of -1.0 mmol/L versus the >10 mmol/L benefit management had guided for, forcing discontinuation of further development. The post hoc explanation is still not reassuring: lower Trikafta exposures, non-adherence in a small 15-patient study, and preclinical assay concerns all weaken confidence that the company’s CFHBE platform truly translates into meaningful clinical benefit. With SION-719 removed from estimates, SION-451 pushed to FY33, cash projected at about $268 million exiting 2Q26 and runway into 4Q28, the stock faces delayed catalysts, financing risk, and limited near-term support.